This article is more than 5 years old. Information may no longer be current.

Phase 3 trial of Roclatan begins in Europe

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aerie Pharmaceuticals has begun patient dosing in a phase 3 European trial of Roclatan for lowering IOP in patients with open-angle glaucoma or ocular hypertension, according to a company press release.

Roclatan (netarsudil 0.02%/latanoprost 0.005% ophthalmic solution) is a once-daily eye drop. The two-arm, 6-month Mercury 3 safety trial will enroll approximately 500 patients and provide a 90-day interim efficacy readout comparing the fixed-dose combination therapy to Ganfort (bimatoprost/timolol, Allergan), the release said.

The trial, conducted primarily in the United Kingdom, France, Germany, Italy, Spain and Belgium, will help with regulatory approval and commercialization in Europe and is not needed for U.S. approval.

The company expects to begin a Rhopressa (netarsudil ophthalmic solution 0.02%) clinical program for the Japanese market later this year, according to Vicente Anido Jr., PhD, chairman and CEO of Aerie.